Accepted at 7:56 p.m. Oct, 31, 2023 by Joe
Author: Ahmed7
Related Note: 1473986353147 1
Rationale for change

the new FA2022 does not list plasmapheresis as initial treatment, its mainly supportive in AMBOSS, plasmapheresis is only indicated in REFRACTORY cases (per AMBOSS)

https://next.amboss.com/us/article/rL0f_g?q=hemolytic%20uremic%20syndrome#Z759bb631d23a3535c2b55dfd91c4807b

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Empty field
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::#Pathoma::04_Hemostasis::01_Primary_Hemostasis_&_Related_Bleeding_Disorders #AK_Step2_v12::#AMBOSS::g30F3f #AK_Step1_v12::#Physeo::11_Pathology::10_HemeOnc_Pathology::01_Primary_Hemostasis #AK_Step1_v12::#AMBOSS::p-0Lyi #AK_Other::AnKing_Image::Mujeeb::Platelet_disorders #AK_Step2_v12::#AMBOSS::S30y3f #AK_Step1_v12::^Systems::HemeOnc::Hematology #AK_Step2_v12::#Bootcamp::Pediatrics::04_Hematology_and_Oncology::01_Anemias::04_Hemolytic_Anemias #AK_Other::#AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Hematology_&_Oncology::Pathoma_Hematology #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Hematology-Oncology::Approach_To_Bleeding #AK_Other::Only_Step_1&2_Overlap #AK_Step1_v12::#Physeo::^physeo_image_update #PANCE::HEME::coagulation_disorders #AK_Step2_v12::#FirstAid::07_Hematology::03_Platelet_Disorders::02_Hemolytic_Uremic_Syndrome #AK_Other::AnKing_Image::!Subjects::Hematology::Platelet_disorders #AK_Step1_v12::#NBME::Free120::2024 #AK_Step3_v12::#UWorld::105854 #AK_Step1_v12::#AMBOSS::eQaxE4 #AK_Step1_v12::#Low/HighYield::4-LowerYield #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::19_Platelet_Disorders #AK_Step1_v12::#Pixorize::01_Biochemistry::18_Platelet_Disorders::07_Hemolytic_Uremic_Syndrome_(HUS) #AK_Step2_v12::#SketchyPeds::07_Nephrology_&_Urology::02_Infectious_&_Sequelae::01_Hemolytic_Uremic_Syndrome #AK_Step2_v12::#AMBOSS::KDaU25 #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::18_Thrombotic_microangiopathies::*Hemolytic_uremic_syndrome #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::06_Platelets::04_Thrombotic_Microangiopathies